Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2020 Apr;8(4):313-324. doi: 10.1016/S2213-8587(20)30030-9. Epub 2020 Mar 2.
Lancet Diabetes Endocrinol. 2020.
PMID: 32135138
Clinical Trial.
Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Larsen EL, Poulsen HE, Goetze JP, Møller HJ, Vilsbøll T, Andersen HU, Knop FK.
Johansen NJ, et al. Among authors: schluntz c.
Diabetes Obes Metab. 2020 Sep;22(9):1639-1647. doi: 10.1111/dom.14078. Epub 2020 Jun 16.
Diabetes Obes Metab. 2020.
PMID: 32543021
Clinical Trial.
Item in Clipboard
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Hartmann B, Holst JJ, Vilsbøll T, Andersen HU, Knop FK.
Johansen NJ, et al. Among authors: schluntz c.
Diabetes Obes Metab. 2022 Feb;24(2):221-227. doi: 10.1111/dom.14568. Epub 2021 Oct 18.
Diabetes Obes Metab. 2022.
PMID: 34617375
Clinical Trial.
Item in Clipboard
Cite
Cite